Dr. Kudchadkar on the FDA Approval of Avelumab in Merkel Cell Carcinoma

Ragini Kudchadkar, MD, assistant professor, Department of Hematology and Medical Oncology, associate director, Hematology and Medical Oncology Fellowship Program-Clinical/Service, Emory University School of Medicine, discusses the FDA approval of avelumab for the treatment of patients with Merkel cell carcinoma.

Ragini Kudchadkar, MD, assistant professor, Department of Hematology and Medical Oncology, associate director, Hematology and Medical Oncology Fellowship Program-Clinical/Service, Emory University School of Medicine, discusses the FDA approval of avelumab for the treatment of patients with Merkel cell carcinoma.

Related Content:

Winship Cancer Institute of Emory UniversityOncLive TVImmuno-Oncology
Dr Weiss on the Role of Breast Imaging in Breast Cancer Treatment Decision-Making
Dr Herbst on the Evolution of EGFR Inhibition in Lung Cancer
Data for Nivolumab Plus AVD Could Help Harmonize Treatment of Older and Younger Advanced-Stage Hodgkin Lymphoma